Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Johnson and Johnson
Harvard Business School
Colorcon
Mallinckrodt

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,933,310

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,933,310 protect, and when does it expire?

Patent 6,933,310 protects RADICAVA and is included in one NDA.

This patent has seven patent family members in six countries.

Summary for Patent: 6,933,310
Title: Therapeutic agent for amyotrophic lateral sclerosis (ALS)
Abstract:An object of the present invention is to provide a novel medicament with which motor neuron diseases can be treated. According to the present invention, there is provided a therapeutic agent for motor neuron diseases which comprises 3-methyl-1-phenyl-2-pirazoline-5-on or physiologically acceptable salts thereof as an active ingredient.
Inventor(s): Ikeda; Ken (Tokyo, JP)
Assignee: Mitsubishi Pharma Corporation (Osaka, JP)
Application Number:10/399,961
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,933,310

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mitsubishi Tanabe RADICAVA edaravone SOLUTION;INTRAVENOUS 209176-001 May 5, 2017 RX Yes Yes   Start Trial   Start Trial TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)   Start Trial
Mitsubishi Tanabe RADICAVA edaravone SOLUTION;INTRAVENOUS 209176-002 Nov 15, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,933,310

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-324476Oct 24, 2000
PCT Information
PCT FiledNovember 13, 2000PCT Application Number:PCT/JP00/07994
PCT Publication Date:May 02, 2002PCT Publication Number: WO02/34264

International Family Members for US Patent 6,933,310

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 303808   Start Trial
Germany 60022560   Start Trial
European Patent Office 1405637   Start Trial
Spain 2248144   Start Trial
Japan 3758164   Start Trial
Japan WO2002034264   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Boehringer Ingelheim
Baxter
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.